No Data
Fulcrum Therapeutics Shares Rise 26% on Sickle Cell Disease Market Opportunity
12 Health Care Stocks Moving In Thursday's Intraday Session
Fulcrum Therapeutics Potential Winner After Pfizer Pulls Oxbryta -- Market Talk
Express News | Fulcrum Therapeutics Shares up 31% After Rival Pfizer Withdraws Sickle Cell Disease Treatment
Fulcrum Therapeutics to Cut Jobs, Reprioritize R&D Activities
Fulcrum Reduces Its Workforce